AstraZeneca plc (AZN) Ordinary US$0.25

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
AstraZeneca receives positive Phase III trial results from Enhertu study
22 April 2025 08:05
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it had received "positive high-level results" from a Phase III trial on its Enhertu candidate, developed in conjunction with Daiichi...
-
London close: Stocks fall as China retaliates to latest US tariffs
9 April 2025 15:07
(Sharecast News) - London stocks fell sharply on Wednesday, with investors reacting to heightened geopolitical tensions after China unveiled retaliatory tariffs in response to a sweeping 104% import charge...
-
AstraZeneca's Enhertu gets further EU approval
4 April 2025 07:02
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor...
-
London close: Stocks slide in global reaction to Trump tariffs
3 April 2025 15:29
(Sharecast News) - London stocks closed sharply lower on Thursday as global markets reacted negatively to US president Donald Trump's unexpectedly aggressive global tariff policy announced overnight.
-
UK pharma stocks avoid selloff
3 April 2025 10:18
(Sharecast News) - GSK and AstraZeneca avoided the selloff on Thursday as pharmaceutical products were exempt from Donald's Trump's tariffs.
-
AstraZeneca makes regulatory progress with Imfinzi, Calquence
31 March 2025 07:21
(Sharecast News) - AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its oncology therapies, Imfinzi and Calquence, marking progress in its...
-
AstraZeneca spending $2.5bn on new R&D centre, biotech deals in China
21 March 2025 11:17
(Sharecast News) - Pharma giant AstraZeneca announced on Friday that it is investing $2.5bn in a new global R&D centre in China, along with major research and manufacturing agreements with three of the...
-
AstraZeneca buys biotech firm Esobiotec for up to $1bn
17 March 2025 07:21
(Sharecast News) - AstraZeneca announced on Monday that it is spending up to $1bn to acquire Belgian biotech firm EsoBiotec, which it says has the potential to "transform" cell therapy.
-
AstraZeneca hails trial results for imfinzi on gastric cancer
7 March 2025 07:03
(Sharecast News) - AstraZeneca said its Imfinzi drug when used with chemotherapy had shown "statistically significant and clinically meaningful improvement" in survival in resectable early-stage...
-
AstraZeneca's Imfinzi gets recommended for fresh EU approval
3 March 2025 07:26
(Sharecast News) - AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for adults with resectable non-small cell lung cancer (NSCLC) at high...
-
AstraZeneca's camizestrant shows promise in breast cancer trial
26 February 2025 08:07
(Sharecast News) - AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in the...
-
London close: Stocks slip as US jobless claims rise
20 February 2025 16:06
(Sharecast News) - London equities ended lower on Thursday as investors reacted to a higher-than-expected rise in US jobless claims and a decline in UK consumer confidence.
Company announcements Announcements
-
Enhertu combination improved PFS in 1L HER2+ mBC
22 April 2025 07:00
AstraZeneca
-
Result of AGM
11 April 2025 17:30
AstraZeneca
-
Imfinzi approved in EU for AEGEAN
4 April 2025 07:05
AstraZeneca
-
Enhertu approved in EU in post-ET breast cancer
4 April 2025 07:00
AstraZeneca
-
Total Voting Rights
1 April 2025 15:00
AstraZeneca
-
Calquence recommended for EU approval in 1L MCL
31 March 2025 07:05
AstraZeneca
-
Imfinzi approved in the US for bladder cancer
31 March 2025 07:00
AstraZeneca
-
AZN invests $2.5bn in Beijing R&D & manufacturing
21 March 2025 10:58
AstraZeneca
-
Eneboparatide Phase III trial met primary endpoint
17 March 2025 07:10
AstraZeneca
-
Imfinzi approved in EU for limited-stage SCLC
17 March 2025 07:05
AstraZeneca
-
AstraZeneca to acquire EsoBiotec
17 March 2025 07:00
AstraZeneca
-
Director/PDMR Shareholding
7 March 2025 15:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.